Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 USDMF, 1 NDC API

1 API Suppliers
1 USDMF
1 NDC API

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Zoledronic acid disodium, Zoledronate disodium anhydrous, 165800-07-7, 5csv5k1879, 131654-46-1, Unii-5csv5k1879

Molecular Formula

C₅H₈N₂Na₂O₇P₂

Molecular Weight

316.05 g/mol

InChI Key

OPQQEYHAVUNQNA-UHFFFAOYSA-L

FDA UNII

5CSV5K1879

Zoledronate Disodium is the disodium salt form of zoledronate, a synthetic imidazole, third generation bisphosphonate analog of pyrophosphate with antiresorptive activity. Zoledronate binds to hydroxyapatite crystals in the bone matrix and inhibits farnesyl pyrophosphate (diphosphate) synthase, thereby preventing protein prenylation within the mevalonate pathway. This leads to the loss of downstream metabolites essential for osteoclast function, leading to the induction of apoptosis and eventually, osteoclast-cell death. By preventing osteoclast-mediated bone resorption, zoledronate decreases bone turnover and stabilizes the bone matrix.

1 2D Structure

Zoledronate Disodium

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-2-imidazol-1-ylethyl]phosphinate

2.1.2 InChI

InChI=1S/C5H10N2O7P2.2Na/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;/q;2*+1/p-2

2.1.3 InChI Key

OPQQEYHAVUNQNA-UHFFFAOYSA-L

2.1.4 Canonical SMILES

C1=CN(C=N1)CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]

2.2 Other Identifiers

2.2.1 UNII

5CSV5K1879

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Zoledronic Acid Disodium

2. Zoledronate Disodium Anhydrous

3. 165800-07-7

4. 5csv5k1879

5. 131654-46-1

6. Unii-5csv5k1879

7. Dtxsid80157167

8. Akos015969312

9. J-010228

10. Q27261841

11. Phosphonic Acid, (1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bis-, Disodium Salt

12. Phosphonic Acid, P,p'-(1-hydroxy-2-(1h-imidazol-1-yl)ethylidene)bis-, Sodium Salt (1:2)

2.4 Create Date

2006-03-21

3 Chemical and Physical Properties

Molecular Formula	C₅H₈N₂Na₂O₇P₂
Molecular Weight	316.05 g/mol
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	4
Exact Mass	315.96021316 g/mol
Monoisotopic Mass	315.96021316 g/mol
Topological Polar Surface Area	159 Å²
Heavy Atom Count	18
Formal Charge	0
Complexity	322
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3